bluebird bio Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : bluebird bio Inc.

BLUE 4.970

0.0%

Jun 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Biotech Jim	3/18/2014 8:47:32 AM
	Read Replies (2) of 163

Advances to CAR-T technology continue, this time with a safety switch if the cytokine release syndrome (or other side effects) becomes too intense, by Bellicum Pharmaceuticals Inc. prnewswire.com "First Cancer Trial Launched Using CAR T Cells Engineered with a Safety SwitchNCI study to investigate whether third generation CAR T Cells can be eliminated if they become harmful" "Bellicum's CaspaCIDe® safety switch is designed to enable more cancers to be safely treated with CAR T cells" Note that Bellicum Pharmaceuticals is a privately held cellular immunotherapy company headquartered in Houston, Texas.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next